Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative bacterial lipopolysaccharide (LPS), also known as endotoxin, is a major glycolipid component of the outer leaflet of the outer membrane of Gram-negative bacteria. It plays a critical role in maintaining the structural integrity of the bacterial cell envelope and acts as a highly effective physical and chemical permeability barrier against toxic compounds, including many antibiotics. Structurally, LPS consists of three domains: a hydrophobic lipid A moiety that anchors the molecule in the outer membrane, a core oligosaccharide, and a highly variable O-antigen polysaccharide chain exposed to the extracellular environment. The lipid A portion is highly conserved and is responsible for the endotoxic activity of LPS, triggering a robust inflammatory response in mammalian hosts via the TLR4/MD-2 receptor complex. Because of its essential role in bacterial survival and outer membrane stability, LPS is a major therapeutic target. Cationic polypeptide antibiotics, such as polymyxin B and colistin (polymyxin E), directly bind to the negatively charged lipid A phosphate groups of LPS, displacing stabilizing divalent cations (calcium and magnesium) and disrupting the outer membrane, which leads to cell lysis and bactericidal activity. Additionally, novel therapeutic strategies target the biosynthesis of LPS (e.g., LpxC inhibitors) or its transport machinery (e.g., zosurabalpin targeting the LptB2FGC complex), highlighting the central importance of LPS in combating multidrug-resistant Gram-negative bacterial infections.
Direct binding to the lipid A moiety of lipopolysaccharide, displacing divalent cations (calcium and magnesium) that stabilize the outer membrane. This disrupts membrane integrity, causing leakage of cytoplasmic contents and bactericidal activity. Additionally, novel agents can inhibit the transport of lipopolysaccharide from the inner membrane to the outer membrane by targeting the LptB2FGC complex, leading to toxic intracellular accumulation of lipopolysaccharide and cell death.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial lipopolysaccharide (LPS).